Show Summary Details

Quick Reference

An incretin mimetic approved for treatment of type 2 diabetes. It is a synthetic derivative of exendin-4, an agonist of receptors of glucagon-like peptide-1 (GLP-1) and is resistant to inactivation by dipeptidylpeptidase-4. TN Byetta.

Subjects: Clinical Pharmacology and Therapeutics.

Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.